Preoperative CA-125 levels in patients with hereditary compared to sporadic epithelial ovarian carcinoma Journal Article
| Authors: | Leitao, M.; Boyd, J. |
| Article Title: | Preoperative CA-125 levels in patients with hereditary compared to sporadic epithelial ovarian carcinoma |
| Abstract: | Objective. The aim of this study was to determine whether a significant difference in preoperative CA-125 levels exists between patients with BRCA-associated hereditary ovarian carcinoma and those with sporadic ovarian carcinoma and whether the CA-125 level predicts the probability of optimal cytoreductive surgery. Methods. From a retrospective cohort of 189 consecutive ovarian cancer patients genotyped for BRCA mutation status, data on preoperative CA-125 levels were available for 49/88 (56%) hereditary cases and 43/101 (43%) sporadic cases. Data on the extent of surgical cytoreduction were obtained for all 92 patients with available CA-125 data. Comparison of preoperative CA-125 levels between hereditary and sporadic groups was assessed using the Kruskal-Wallis ξ2 test. Correlation of surgical cytoreduction with preoperative CA-125 level was assessed using Fisher's exact test. Results. Mean preoperative CA-125 levels were not significantly different among BRCA1 (2289 U/ml), BRCA2 (2586 U/ml), and sporadic (3307 U/ml) cases (P = 0.5). For hereditary cases, optimal cytoreduction was achieved in 59% of patients with preoperative CA-125 levels of <500 U/ml and in 52% of patients with preoperative levels >500 U/ml. For sporadic cases, optimal cytoreduction was achieved in 62% of patients with CA-125 levels of <500 U/ml and in 20% of patients with levels >500 U/ml (P = 0.01). Conclusions. Preoperative CA-125 levels are not significantly different for patients with hereditary compared to sporadic ovarian carcinoma. The probability of optimal cytoreduction is independent of the preoperative CA-125 level for hereditary cases, but optimal cytoreduction is significantly less likely for sporadic cases with CA-125 levels of >500 U/ml. © 2002 Elsevier Science (USA). |
| Keywords: | controlled study; treatment outcome; cancer surgery; gene mutation; major clinical study; preoperative care; preoperative evaluation; ovarian neoplasms; genotype; brca1 protein; brca2 protein; retrospective study; prediction; correlation analysis; genes, brca1; genes, brca2; antigen detection; ovary carcinoma; epithelial cells; familial cancer; ca 125 antigen; ca-125 antigen; jews; germ-line mutation; reference value; kruskal wallis test; humans; prognosis; human; female; priority journal; article |
| Journal Title: | Gynecologic Oncology |
| Volume: | 84 |
| Issue: | 3 |
| ISSN: | 0090-8258 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2002-03-01 |
| Start Page: | 413 |
| End Page: | 415 |
| Language: | English |
| DOI: | 10.1006/gyno.2001.6538 |
| PUBMED: | 11855879 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Export Date: 14 November 2014 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work